Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review DOI Open Access
Jason D. Merker, Geoffrey R. Oxnard, Carolyn C. Compton

et al.

Archives of Pathology & Laboratory Medicine, Journal Year: 2018, Volume and Issue: 142(10), P. 1242 - 1253

Published: March 5, 2018

Purpose.— Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society Oncology and College Pathologists summarizes current information about clinical ctDNA assays provides a framework for future research. Methods.— An Expert Panel conducted literature on solid tumors, including preanalytical variables, validity, interpretation reporting, validity utility. Results.— The search identified 1338 references. Of those, 390, plus 31 references supplied by Panel, were selected full-text review. There 77 articles inclusion. Conclusions.— evidence indicates that testing optimally performed plasma collected cell stabilization or EDTA tubes, with tubes processed within 6 hours collection. Some have demonstrated utility certain types advanced cancer; however, there insufficient majority cancer. Evidence shows discordance between results genotyping specimens, supports tissue confirm undetected tests. no little early-stage cancer, treatment monitoring, residual disease detection. suggest are useful cancer screening, outside trial. Given rapid pace research, reevaluation will shortly be required, along development tools guidance practice.

Language: Английский

Liquid biopsies come of age: towards implementation of circulating tumour DNA DOI
Jonathan C. M. Wan, Charles Massie,

Javier García-Corbacho

et al.

Nature reviews. Cancer, Journal Year: 2017, Volume and Issue: 17(4), P. 223 - 238

Published: Feb. 24, 2017

Language: Английский

Citations

2177
A view on drug resistance in cancer DOI Open Access
Neil Vasan, José Baselga, David M. Hyman

et al.

Nature, Journal Year: 2019, Volume and Issue: 575(7782), P. 299 - 309

Published: Nov. 13, 2019

Language: Английский

Citations

2077
Integrating liquid biopsies into the management of cancer DOI
Giulia Siravegna, Silvia Marsoni, Salvatore Siena

et al.

Nature Reviews Clinical Oncology, Journal Year: 2017, Volume and Issue: 14(9), P. 531 - 548

Published: March 2, 2017

Language: Английский

Citations

1632
Liquid biopsy and minimal residual disease — latest advances and implications for cure DOI
Klaus Pantel, Catherine Alix‐Panabières

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 409 - 424

Published: Feb. 22, 2019

Language: Английский

Citations

865
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers DOI Creative Commons
Pedram Razavi,

Matthew T. Chang,

Guotai Xu

et al.

Cancer Cell, Journal Year: 2018, Volume and Issue: 34(3), P. 427 - 438.e6

Published: Sept. 1, 2018

Language: Английский

Citations

818
Application of Cell-free DNA Analysis to Cancer Treatment DOI
Ryan B. Corcoran, Bruce A. Chabner

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(18), P. 1754 - 1765

Published: Oct. 31, 2018

Interview with Dr. Ryan Corcoran on the potential clinical applications of cell-free DNA analysis in patients cancer. (10:36)Download The capacity to detect new cancers, treatment-resistant variants, and tumor heterogeneity by noninvasive technology basis blood promises revolutionize cancer detection, prevention, treatment.

Language: Английский

Citations

783
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer DOI Creative Commons
Gabriel N. Hortobágyi, Salomon M. Stemmer,

H. A. Burris

et al.

Annals of Oncology, Journal Year: 2018, Volume and Issue: 29(7), P. 1541 - 1547

Published: April 25, 2018

BackgroundThe phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Here, we report updated efficacy safety data, together exploratory biomarker analyses, from the study.Patients methodsA total of 668 postmenopausal women HR+, HER2– recurrent/metastatic cancer were randomized (1 : 1; stratified by presence/absence liver and/or lung metastases) to (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) (2.5 continuous) or letrozole. The primary end point was locally assessed PFS. key secondary overall (OS). Other points included response rate (ORR) safety. Biomarker analysis an point.ResultsAt time second interim analysis, median duration follow-up 26.4 months. Median PFS 25.3 months [95% confidence interval (CI) 23.0–30.3] 16.0 (95% CI 13.4–18.2) (hazard ratio 0.568; 95% 0.457–0.704; log-rank P = 9.63 × 10−8). Ribociclib benefit maintained irrespective PIK3CA TP53 mutation status, Rb, Ki67, p16 protein expression, CDKN2A, CCND1, ESR1 mRNA levels. more pronounced wild-type altered tyrosine kinase genes. OS data remain immature, 116 deaths observed; 50 arm 66 0.746; 0.517–1.078). ORR 42.5% 28.7% all treated letrozole, respectively, 54.5% 38.8%, measurable disease. Safety results, after further 11.1 follow-up, comparable those reported at first no new unexpected toxicities observed, evidence cumulative toxicity.ConclusionsThe improved outcomes tolerability observed are longer relative monotherapy.Clinical trials numberNCT01958021

Language: Английский

Citations

718
Overcoming Endocrine Resistance in Breast Cancer DOI Creative Commons
Ariella B. Hanker, Dhivya R. Sudhan, Carlos L. Arteaga

et al.

Cancer Cell, Journal Year: 2020, Volume and Issue: 37(4), P. 496 - 513

Published: April 1, 2020

Language: Английский

Citations

658
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer DOI
Charlotte Fribbens, Ben O’Leary, Lucy Kilburn

et al.

Journal of Clinical Oncology, Journal Year: 2016, Volume and Issue: 34(25), P. 2961 - 2968

Published: June 7, 2016

ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of on sensitivity to standard therapies two phase III randomized trials that represent development current for estrogen receptor-positive cancer.In a prospective-retrospective analysis, we available archived baseline plasma from SoFEA (Study Faslodex Versus Exemestane With or Without Arimidex) trial, which compared exemestane with fulvestrant-containing regimens patients nonsteroidal AI and PALOMA3 (Palbociclib Combined Fulvestrant Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer After Endocrine Failure) fulvestrant plus placebo palbociclib progression after receiving endocrine therapy. were analyzed multiplex digital polymerase chain reaction.In SoFEA, found 39.1% (63 161), whom 49.1% (27 55) polyclonal, rates mutation detection unaffected delays processing archival plasma. Patients had improved progression-free survival (PFS) taking (n = 45) 18; hazard ratio [HR], 0.52; 95% CI, 0.30 0.92; P .02), whereas wild-type similar PFS either treatment (HR, 1.07; 0.68 1.67; .77). In PALOMA3, 25.3% (91 360), 28.6% (26 91) associated acquired resistance AI. both mutant 0.43; 0.25 0.74; .002) 0.49; 0.35 0.70; < .001).ESR1 analysis may help direct choice further endocrine-based Additional confirmatory studies required.

Language: Английский

Citations

642
The emerging role of cell-free DNA as a molecular marker for cancer management DOI Creative Commons
Abel J. Bronkhorst, Vida Ungerer, Stefan Holdenrieder

et al.

Biomolecular Detection and Quantification, Journal Year: 2019, Volume and Issue: 17, P. 100087 - 100087

Published: March 1, 2019

An increasing number of studies demonstrate the potential use cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing full cfDNA requires (i) optimization standardization preanalytical steps, (ii) refinement current analysis strategies, and, perhaps most importantly, (iii) significant improvements our understanding its origin, physical properties, dynamics circulation. The latter knowledge is crucial interpreting associations between changes baseline characteristics clinical manifestations cancer. In this review we explore recent advancements highlight gaps concerning each point contact different stages cancer management.

Language: Английский

Citations

488